This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Subfoveal choroidal thickness and PCV

Subfoveal choroidal thickness and PCV
Reviewed by Saruban Pasu

1 April 2018 | Saruban Pasu | EYE - Vitreo-Retinal

This report studies the prognostic factors for visual improvement and the need for additional treatments at one year after the initial combination therapy of intravitreal ranibizumab injection or intravitreal aflibercept injection followed by PDT in eyes with PCV. Fifty-six eyes with treatment-naive subfoveal PCV were retrospectively reviewed during the 12-month follow-up period after the initial combination therapy involving intravitreal injection of anti-VEGF agents followed by PDT. Thirty-three eyes had aflibercept and 23 eyes had ranibizumab. Intravitreal injections were given one week prior to PDT. The subjects were followed up at three-month intervals until retreatment. Retreatment was conducted when residual or recurrent exudative changes were seen on OCT. There were no significant differences between each of the two intravitreal groups. In each of the groups both mean central macular thickness and subfoveal choroidal thickness were significantly reduced at every three month visit. A better visual outcome at 12 months was correlated with better initial BCVA, baseline smaller greatest liner diameter (on ICG), and baseline greater subfoveal choroidal thickness. In contrast, the visual gain from the baseline BCVA was correlated with worse initial BCVA, baseline smaller greatest linear diameter (on ICG), and baseline greater subfoveal choroidal thickness. Retreatment during the follow-up period was not significantly different between the two groups. Logistic regression analysis revealed that only a lesser subfoveal choroidal thickness was associated with the need for additional treatments involving intravitreal injection of anti-VEGF agents with or without PDT during the 12-month follow-up period after the initial combination therapy (P = 0.036). This is the first report demonstrating that baseline subfoveal choroidal thickness is a predictive factor of visual improvement at 12 months after combination therapy involving intravitreal ranibizumab injection or intravitreal aflibercept injection followed by PDT in eyes with PCV.

Choroidal thickness as a prognostic factor of photodynamic therapy with aflibercept or ranibizumab for polypoidal choroidal vasculopathy.
Sakirada Y, Sugiyama A, Tanabe N, et al.
RETINA
2017;37(10):1866-72.
Share This
CONTRIBUTOR
Saruban Pasu

Moorfields Eye Hospital, London, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency